Kyleena

Alternative Name: LNG Contraceptive IUS (LCS); LCS16

Description: A new low-dose levonorgestrel contraceptive intrauterine systems (LCS), Kleena(R) delivers 16 µg/24h and is effective for 5 years. Kyleena is similar to Mirena, but with a drug content of only 19.5 mg LNG (as opposed to 52mg LNG).

Product Details

User: Female

Hormonal: Yes

Delivery Method: Intrauterine

Duration Type: Long-acting

Duration: 5 years

Regimen:
  • Single insertion

Dose: 16 microg/24 h

Active Pharmaceutical Ingredient (API):
  • levonorgestrel

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Bayer HealthCare

Project Phase: Limited Market Availability

Development Stage: SRA/WHO PQ Approved

Active Development: Yes

Status Details:
  • The U.S. Food and Drug Administration (FDA) approved Kyleena in September 2016.
  • Kyleena will be available in the U.S. in October 2016.
  • In Nov. 2015, Bayer preregistered the product for contraception in the European Union.

Additional Information

References:

Footnotes:

Vertical Tabs

Print